TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Piperonyl Butoxide

CAS 51-03-6

Piperonyl Butoxide (CAS 51-03-6) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Piperonyl Butoxide
CAS Number
51-03-6
UNII
LWK91TU9AH
InChIKey
FIPWRIJSWJWJAI-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1201131
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1201131 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 28163.72857142857 nM 13 -
- IC50 5200 nM 6 -
- AC50 12854.733333333332 nM 3 -
Cytochrome P450 3A4
Enzyme
IC50 5.52 - Homo sapiens
Cytochrome P450
Enzyme
INHIBITOR - - Pediculus humanus subsp. corporis
SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
PIPERONYL BUTOXIDE 8345 SU MTHSPL
piperonyl butoxide 8345 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Piperonyl Butoxide used for in pharmaceutical contexts?

Piperonyl Butoxide (CAS 51-03-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Piperonyl Butoxide?

No adverse-event association or SIDER side-effect rows are rendered for Piperonyl Butoxide in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Piperonyl Butoxide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Piperonyl Butoxide with EU status "prohibited".

What clinical phase is Piperonyl Butoxide in?

Piperonyl Butoxide is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Piperonyl Butoxide?

Piperonyl Butoxide has 5 bioactivity rows in this page query. Rendered target entries include Cytochrome P450 3A4, Cytochrome P450.